FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									
	OMB Number: Estimated average burd									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Emmens Matthew					2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]					(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				ner		
(Last)	(F	irst)	(Middle)								X	Officer (below)	give title		Other (sp below)	pecify	
C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 07/14/2010							President & CEO					
130 WAVERLY STREET				_	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc	6. Individual or Joint/Group Filing (Check Applicable					
(Street)	IDGE M	·A	02139								Line)	_	,	•	ing Person One Reporti	ng	
(City)	(S	tate)	(Zip)									Person	,				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				2. Transact Date (Month/Day	Execution Date		Date,	Code (Instr.		d (A) or r. 3, 4 and 5)	s. Amount of Securities Beneficially Owned Following Reported		Form: Direct I (D) or Indirect I (I) (Instr. 4)		. Nature of ndirect seneficial ownership		
							Code V	Amount	(A) or (D)	Price	Transactio	ion(s)			nstr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	лі(э)			
Stock Option	\$33.82	07/14/2010		A		118,000		10/14/2010 ⁽¹⁾	07/13/2020	Common Stock	118,000	\$0	118,000	0	D		

Explanation of Responses:

 $1.\ Right to buy under 2006\ Stock\ and\ Option\ Plan,\ vesting\ in\ 16\ quarterly\ installments\ from\ 07/14/2010.$

Remarks:

Valerie L. Andrews, Attorney-

In-Fact

** Signature of Reporting Person Date

07/16/2010

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.